The very first episode of FoGCast is out now!
We’re kicking off with an incredible guest: Jillian Hastings-Ward MBE – a leading voice for patient advocacy in genomic medicine. Jillian has spent years ensuring that research stays ethical, accessible and truly centred on people, and we were delighted to have the chance to chat to her recently.
In this episode, Jillian shares her powerful personal journey and talks about the real value of patient voices in shaping research, the importance of building communities around rare conditions, and why human-to-human connection must remain at the heart of genomics – even in the age of AI.
It’s a conversation full of honesty, hope and insights for researchers, clinicians, and advocates alike.
Listen now on your favourite platform or watch the video below.
Please note transcript has been edited for clarity and brevity.
Lyndsey: Hello everybody, and welcome to FoGCast. Today, we’re thrilled to welcome Jillian Hastings-Ward, a powerful advocate for patient involvement in genomic medicine. From her critical role as the chair of the Participant Panel at Genomics England to her current position as patient and public voice representative at the Rare Diseases Advisory Group, Jillian has helped shape policies that ensure research remains ethical, accessible and human centred, and we’re honoured to have her join us today. Jillian, how are you doing?
Jillian: Thank you very much. I’m really well.
Lyndsey: Tell us a bit about yourself. How have you got to where you are today?
Jillian: Well, the start of my story was when my son was very small. He’s 11 now, so it feels like a long time. He was born with an undiagnosed genetic disorder that became apparent over the first couple of years of his life, and by the time he was two, he developed epilepsy as well as dystonia and severe developmental delays. He was really struggling, and we didn’t really know why. So, we were invited to join the 100,000 Genomes Project, as it was then. We were among the first cohort recruited by St George’s in London, and we had our whole genome sequenced as a family, and in the fullness of time, they came back with a result which had not been seen in the NHS before. Our clinical geneticist there, Professor Sahar Mansour, who’s fabulous, was keen to speak to us about the tentative result that had come back and see whether any of the world’s published literature about this gene sounded like something that we’d seen at home. So, it was a definite teamwork exercise there, for us to look at the tentative finding that had come back and decide that, yes, the phenotype that was being described in these papers did look a lot and behave a lot like our son. Together, we had the first genetic diagnosis of a GRIN1 genetic disorder in Britain, and that was really exciting, to finally know what it was that was causing us troubles, but also to be able to be part of that teamwork exercise.
So, having found his disorder, we were now able to find other people around the world who shared it through the power of social media. In the space of a weekend, we were able to get connected with the organisation in America who were just starting to lay the groundwork there and over the following few years, I became a founding board member of the CureGRIN Foundation, which founded itself in America because the state of Colorado was the only place in the world that we had two people who were able to be in the same place to sign the same chequebook at the same time, which seems incredible these days! But it was a really interesting start. The CureGRIN Foundation has gone from strength to strength, and I’m really delighted that they’re carrying on.
And in the meantime, I was able to join the Participant Panel at Genomics England that was just setting up at the time. Leadership in the early days of Genomics England were really keen to make sure that they took on board the advice they’d had from ethicists like Professor Michael Parker and from Dame Sally Davis, who were very keen to make sure that patient voices and research participant voices really fed in to the decisions that were being made about how Genomics England was setting itself up and what it was planning to do with the data that was collecting from all of us volunteers. So again, that was a really wonderful crest of a wave to be invited to be sailing on really. I joined the Participant Panel in time for the first meeting, which was the spring of 2016 and went on to become its chair the following summer, and then chaired it until the summer of 2024 when I stepped down. Originally, nobody was expecting it to last more than five years or so, because that was the original funding window. But as they gradually demonstrated that this project was going to be a success and turned it into the mainstreaming of genomic medicine that we know now, it became apparent that this endeavour was going to carry on and on and on. And I think, at the time, we felt it was important to make sure that the people who were volunteering their time and their expertise to the panel had somewhat of an understanding that there was going to be an end point to their involvement, so that they didn’t feel that they needed to keep contributing and keep drawing on their own lived experiences, which can be quite painful, sometimes for an indefinite period. So, having brought in term limits, I then had to live by it, so I had to step down along with the rest of the first cohort, but the panel itself was going from strength to strength, and I’m delighted, really, to see how they’ve carried forward the mission that we began.
Manuel: How is your son now?
Jillian: He’s not too bad. Thank you. He is still profoundly developmentally delayed, and he’s a full-time wheelchair user. He needs one to one care all the time, but we are beginning to see glimmers of a wider awareness in the world around him, and that’s really exciting. People talk about inch stones rather than milestones in the disability world, and it’s absolutely the case for us that he’s gradually making little steps forward.
Paul: What are the problems that patient advocacy is solving in? What is the situation that you’ve come into, and the general shape of the things that you’re dealing with that we’re trying to fix?
Jillian: It’s an interesting question to think about in that way. I think science can do amazing things, but I think if scientists understand more about how it feels to have a condition that they’re investigating then that can really help them come in from new angles as well. And sometimes there’s been the cases where patient groups can say, well, you know, we understand that the research in our field at the moment is focused on part of a condition. You know, one of our symptoms, but actually the thing that bothers us more is something else. So, maybe if we can encourage researchers to look at the slightly different aspect of a bundle of symptoms, then that brings greater benefit to the to the community as a whole. I think a lot of patient advocacy, or certainly a lot of patient engagement work, can be couched in terms of, oh, we want to hear the stories from the patients, and we want to know about how their lives are, and by implication, how we can help that by doing the work that we as scientists and researchers and clinicians are doing? But there can be a danger there, that if you’re going to be asking someone to share their story in a sort of performative sense, then it’s not necessarily an equal relationship. And what we’re really keen to make sure is that people who are sharing those stories also have an opportunity to shape any conversations that follow on about what might change as a result of hearing that story. That, for me, is the critical part of patient advocacy, to be in the discussions, rather than just up on a platform, really.
I think we’ve got some great examples over the years that have really demonstrated how valuable that can be. One of the things I’m working on at the moment is an online course for people around the world who are interested in the power of patient advocacy and genomics, and we’ve got some wonderful case studies where groups of people have come together because they were either affected by that same condition or they found themselves in similar life circumstances, and have been able to directly influence decisions that have been made about the research that goes forward on the themes that they’re interested in.
At the beginning of 2024 – you might have heard about this now, I am sure Manuel will be familiar, because it has become quite famous – but the RNU4-2 discovery in an area of the genome that had not previously been looked at, has yielded a huge number of new diagnoses for a whole population of patients that had previously been undiagnosed. The discovery of this through the National Genomic Research Library, which was created by Genomics England and by researchers working elsewhere in the world simultaneously, has led to the discovery of… I think there’s maybe about 400 families around the world who, within the space of the last year, have been able to be diagnosed, even if they’ve been living with this condition for quite a long time. With the power of social media as it is now, they were able to get in touch with each other quite rapidly after they had this diagnosis, because, you know, search terms in search engines can just ping you anybody these days, which is wonderful. So, they were already forming a community group when they heard that the scientists and the clinicians who remain involved in finding this condition had put forward a name for it. It was basically just an acronym of a lot of the main characteristics and symptoms, so it was almost unpronounceable, and it didn’t really mean anything to anybody. They discussed among themselves, and they said, well, we like to refer to this as ReNU, because it’s given us a renewed understanding of what’s wrong with our children. And so why couldn’t we call it something like ReNU syndrome, rather than having to call it a string of letters that no one can pronounce or anything like that? And they took that suggestion back to the scientists who agreed with them, and were able to put that forward, and now that’s officially the name of the condition. And that, for me, was a beautiful example of power pushing in a really useful direction, because it means now we’ve got a term that is comfortable for everybody to be using, but it’s also a wonderful flag around which they can bring their community.
Paul: Everyone in this world is very positive about the power of genomics and how this technology is transforming lives and so on. But I would like to hear your perspective, really, from the point of view of a mother of a patient. How does that really contribute, even if there’s no cure? How does that help the family, you know, when you take away all the science and all these wonderful things, and the economics and wonderful stories, the selling bits? I just want to know, how does that really help people’s lives from your perspective?
Jillian: That’s a fair question. Sometimes my husband asks us the same! My answer is always the same, that I think once you have a label for something, it makes it much easier to build a community around that. So, the support that we’re able to pull together from families who are affected by the same condition is absolutely invaluable. And now in Britain, I’m part of an organisation called GRI-UK, which is for families affected by GRIN, GRID, GRIA and GRIK genes – all about glutamate receptors, that’s the GRI – and we’re bringing families together to share their experience. And sometimes it’s just a question of being able to get on a Zoom community call on a Wednesday evening and just have a moan, or share things that you’ve learned going through the system, whether it’s the education system or the health system, that you can pass on to other people whose children are younger and are following you through that process. So really, as a tool for finding community, it’s been a wonderful thing, and I do accept that there’s an awful lot of science that we don’t understand, but there’s also a lot of things happening out there that aren’t going to necessarily bring direct benefits to us in the foreseeable future, but I think there is still a sense of optimism that the more that these things are explored, the more chance we have of finding potential genetic treatments for our own children or those like them who are following on.
Paul: I think we can all see that very real and visceral benefit from just having community. But you know, all of this has come out of genomics, which is frankly complicated, even to all of us who work within it. How did you find the world of genomics when you were being almost forced into it, thrown into it?
Jillian: Yeah, I’m not a scientist by background either, I didn’t even do basic level biology at school. But it’s amazing what you learn when you have to, and if somebody you love is affected by something, then you’re damn well going to go and find out as much about it as you can. So, I think for us, it was quite helpful to hear lots of analogies, in the early days. You know, this idea that your genome is the equivalent of the encyclopaedia of ‘you’, and there are all these letters in it, and some of them are maybe misspelt or not in the right places. That kind of concept was something that was relatively easy to grasp. And I remember a really useful conversation with one of our clinical geneticists, where she was explaining to me what it meant to have that string of letters and numbers in our diagnosis letter, she was explaining about how the different letters that make up a single gene are more like beads on a string rather than Lego blocks. And she was saying, depending which bead is broken, will determine the severity of the impact of this disorder, or whether it’s a profound or less profound impact of the particular spelling mistake on your child. And I’m sure that’s a simplistic way of describing it, I can tell by Manny’s reaction, but I think that what we were able to grasp from that was something that we could then explain to our family members as well. We became advocates for science, and were able to start talking about these kinds of concepts to other people, which was really helpful.
And there’s some functional questions around the GRIN disorders, where you either have a gain of function or a loss of function impact of your particular genetic disorder, and there are two very different treatment routes that would then be possible for you. And again, trying to get your head around what constitutes a gain of function variant versus a loss of function variant was quite tricky as well. So, there we had some analogies about gain of function being too many people trying to get into a revolving door in a building at once, and it always getting blocked up, or loss of function, where the windows don’t even let you in the tunnel. And again, storytelling and analogies were really useful there, and I have tried to educate myself as well. There are enough basic genomics courses available on the internet now, I was able to do a course through the Future Learn platform quite a number of years ago to try and get my head around that. But I think at the time, that was probably more because I was learning through the role I was having with the Participant Panel at Genomics England, and a lot of the conversations that the Panel members were being invited to be part of, especially those of us who are on the Access Review Committee as well, there’s a lot of technical conversation flying around there. And if you can’t grasp at least the basics of that, then you’re not going to be a very effective advocate.
Paul: What more could the establishment, the doctors, do to help communicate what’s going on?
Jillian: I think that’s quite challenging, because different parents have a different appetite for learning about things, and different parts of their audience are going to have a different background in terms of the level of baseline understanding they have. And in some ways, it’s not necessary to know a huge amount about the technical side of genomics to understand that your child has a genetic disorder and it’s affecting them in a particular way, and in some ways, if that is the only part of this picture that you understand, that’s really the nub of what you need you know. I’m not sure that if you have a splice variant that you need to necessarily understand exactly what that is, just to know that that’s the term that you use to talk about it with the experts, then they will understand what that implies. And I think there’s a danger that it can be a bit of a black box, but at the same time, that’s where the trust relationship comes in, that the parents and the families affected by these technical genetic disorders are looking to the professional researchers and clinicians to be doing what needs to be done in the black box and sharing with us the outcome, rather than necessarily all of us understanding the nitty gritty.
On the other hand, though, I think there’s always more to be gained by sharing more information about what you’re doing with the potential audience. And there’s some really nice initiatives happening right now, I’m part of a research project which is currently running through the University of Oxford. We’ve got some money to put together some video explainers for families affected by genetic disorders, and they’re currently working up what sort of question topics they might want to try and cover, and then they’re going to try and road test those with a group of families of varying levels of scientific understanding to try and make sure that they’re hitting the right mark for the world. So, there’s a lot of people trying to innovate in this space as well, but I would say this, yeah, it can be a danger in trying to over explain things. I mean, the nuts and bolts are really what is the name of this thing and can I see how it is affecting my child? And can I find people who are affected by something similar, which will enable us to work together to try and push forward for a treatment.
Manuel: Do researchers risk failing patients. I’m a researcher, and I would like to be a little bit better after this conversation. So, tell me what we need to change?
Jillian: That’s a really interesting question, because when you say that researchers are failing patients, what is it that you think they should be doing that they’re not doing?
Manuel: From my perspective, I’m a bioinformatician, so I’ve always been thinking about the fact that I’m just looking at data. My emphasis is now when I talk, I always think of the face of the people behind these data, because it’s very easy to forget the humanity behind those cold data sets. But that’s a naive way of thinking. Full disclosure, I have a child who’s also severely disabled with Down syndrome, although it’s not a rare genetic disorder, it’s still a genetic disorder. And I know I have some idea of what the process is, the sleepless nights, the uncertainty, even social pressure of ‘why didn’t you have an abortion’, or this kind of thing. There’s a lot of stigma. So, I want to understand your perspective. As a researcher, how can we get better? Even myself, I don’t have the full perspective, and I’m sure that there are going to be lots of things I’m missing. So, I want you to help educate us, what are the gaps that you see? Where do you see the risks, in terms of us delivering what we should be delivering?
Jillian: As I mentioned, I think we trust the researchers to do the technical stuff. But it was lovely to hear you saying that basically every data point has a face, because that’s something I’ve been putting in presentations for years. So, it’s wonderful to hear it coming back to me. And I think it is a really helpful shorthand to remember that all the numbers that we’re crunching here have come from people who volunteer to share this data and are living the real impact. One of the things that we have always advocated through the work with the Participant Panel and beyond is just opening doors and being able to get researchers to meet people who’ve got the condition that they’re interested in researching. Or to at least have an opportunity to interact at some level, so that they can find out more about how the whole of their life is, rather than just that specific part that the researcher is an expert in. With the explosion of new diagnoses that we’ve seen, especially in rare disease thanks to the genomics revolution that’s been coming, there’s now a proliferation of very small support groups of people – who are just a handful of people in some cases – affected by each of these disorders. They exist to be a beacon for other people who are in hard times with the same issue, and they’re quite easy to find on the internet now. So, I think it’s not a difficult job for a researcher, if they have time and inclination to go and have an internet search and see who they can find out there. The older, longer standing platforms like Facebook, are really handy for this because so many of the parent generation are still using that, rather than newfangled TikTok and everything. But I’m sure there’s lots of other channels now as well which people can use, and being able to find them is the first stage to starting that conversation.
And we’ve had some amazing conversations with some of the researchers who are looking at GRIN disorders. Most illuminatingly was when we were talking to a researcher who’s based in Toronto, who has a lab full of mice with GRIN disorders, because she was looking for treatment for dementia or something along those lines. She didn’t know initially that there were humans out there who had this disorder as well. When we were able to meet her for the first time and talk to her, she was really keen to hear about what our humans were like, and we were really keen to hear about what her mice were like, and it turned out they had some stunning characteristics in common that we weren’t expecting. So, yeah, a fondness for staying in warm water, for example, rather than climbing out onto the hill of sand, which you’re supposed to do as a mouse in the experiments that they’re running. Or a liking for fresh air rather than being in the dark, which is, again, not something that a mouse is genetically supposed to do. That was an amazing thing to discover, and we are now delighted that she’s going to carry on finding out more about the genetic impact of our disorders through the work that she’s doing.
When it comes to research that is much more desk based, the number crunching and the bioinformatics and all that end of genomics, I can completely see how it would be very easy to spend your whole life looking at a computer screen and not step out and make that connection for yourself with the people whose data that you’re looking at. I think initiatives such as they have at Genomics England, where in part of the induction week, they have a session where they get to hear from the participant representatives about what it means to be part of the National Genomic Research Library, but also about their ambitions for what these researchers are going to go and do. That can be a real boost at the beginning, and it also starts to humanise the work that you’re doing in that very technical environment, which I think is a good thing.
Personally, I don’t feel like researchers are failing me. I’m excited that there are so many people out there now looking at the scientific basis behind GRIN disorders. And we hear more and more every annual conference that the CureGRIN organisation hold, or the European ones, hopefully we’re hosting one in Britain for the first time next summer as well. You know, every time there’s an event, there’s more and more people want to come and talk at it, and there’s more and more people want to come
and listen.
Paul: It strikes me, Jillian, that all of this takes your support circuit, the people who are on your side, and it makes it an international circuit Then in an amazing way, you’re not reliant upon who you can just find your local area through your local health system, but around the globe.
Maybe this is a bit daring: is there a downside to these genomic diagnoses? Are there some bad things or some uncomfortable things that come with the good?
Jillian: Well, I think for some families, before they have a diagnosis, they’re still hoping it’s not going to be terrible news. And when you do get a diagnosis, then that’s a bit more conclusive, and you have to readjust the parameters in which you’re operating to move forward. And I suppose there can be a downside if you have a genetic diagnosis of a gene which is part of a group of genes, that you might not understand the connection between these different genes, and you might be in danger of setting yourself off down a super specialised path. This actually [might not] be very attractive to researchers to come and investigate, and you may need to broaden out a little bit to make more of a community that is going to be that critical mass to get a researcher to be able to get funding to do some research for you.
I’m a natural optimist, though, so maybe I’m not the right person to answer that question fully, but I think for us, knowing that it was a genetic disorder and knowing that it was a de novo mutation was a particularly helpful thing to know. Because then you don’t need to worry about the rest of your family being affected by it as well. My son has a sister who may one day want to go and have her own children. Other female relatives elsewhere in our family might want to have their own children in due course.
Paul: Am I led to believe you have a course coming up sometime soon?
Jillian: Yes, I’ve been working with Wellcome Connecting Science to put together this course for learners around the world. It’s called The Power of Patient Advocacy in Genomics, which just trips off the tongue, and I’m delighted that we’ve got so many great case studies to share with the world. The course was originally going to be four weeks long, but we’ve had our external reviews back, and they said there’s just so much good content in here. We need to let it breathe a bit, so we’re going to be stretching it out to five weeks, starting middle of September, which is a wonderful position to be in that we’ve had so much we wanted to share. It’s designed to be accessible to an audience of people who are just starting on their genomics journey. So, perhaps families who’ve just been diagnosed, or people who’ve been advocating for patients in other parts of the healthcare and want to learn more about genomics. There’s a good chunk at the beginning where we’re sort of introducing people to the basic principles, because one of the things that we’re keen to make sure is that people who are trying to become effective advocates in the genomics space understand a bit about what the science involves and the consenting processes that brings people into genomics as well, because we’re conscious that the vast majority of people who are benefiting from genomic medicine, or even involved in genomic medicine, at the moment, have done it by choice. In most healthcare systems, you still choose whether you want to have whole genome sequencing or not, and you still have the power to say no. So, the data that is collected about you, obviously your whole genome and your background health data to make sense of that genome, that’s such valuable data that some people are still rightly sceptical about. And so, it’s not as mainstream as some of the other types of medicine that we’ve seen. We felt it was important to explain a bit about what makes genomics special and the value of it, and the importance of trust and ethics and equity in that situation. There’s a good chunk of learning about that near the beginning.
And then we move into lots of case studies, practical examples of where patients, individually or as groups of people, have been advocating on behalf of others or themselves around the world and influencing policy and nomenclature and the approach to research in some cases, examples where patient representatives are getting together to fund research directly or trying to discuss with researchers how they would like things to move forward and be co-applicants on grant funding bids and all sorts of things. And then at the end of our course, we’re concluding with a peer review exercise. We’re inviting our learners to think from their own perspective, if there are any scenarios in their own world where they think it would be helpful to try or anywhere where they’re trying to push some progress forward on behalf of patients, either themselves or people like them. So we’re going to be asking them to think about, what is the situation that you’re in at the moment? What is it that you’re trying to change and improve? What would it take to get there? Who needs to be influenced to make that happen? What does success look like, and what kind of timeframe would be realistic to think about? Trying to get them to proactively think about how that applies in their own context, and then share that learning with each other. I’m really looking forward to seeing what comes out of that, because I think it’s going to be really interesting. The course is free to anybody around the world with an internet connection who wants to come and join it. It’s hosted by the Future Learn platform, which I think is universally accessible, and there’s loads of resources there that people can download and refer to again later, if you wish.
Manuel: You’ve just mentioned equity, and this is something that is very close to my heart. Many people talk about equity, but from your perspective, what does real equity look like for a patient advocate like yourself?
Jillian: There are so many ways you could answer that question. I suppose one of the things that has just come forward in developing this course has been the recognition that some parts of the world are pushing forward with genomic science faster than others. Some parts of the world have healthcare systems that can support the implementation of that into routine healthcare, and some don’t yet. And so I think there’s a lot of useful work being done, thinking about the basic level of service that’s necessary in order to implement some form of genomic medicine in the country, rather than the topflight that really rich West countries are able to fund. And I think that’s there’s a whole work stream that’s going on in that, the Wellcome Trust are doing quite a lot of work in that space, and lots of other global organisations are looking to see how they can try and roll out the learning without also necessitating enormous expenditure in these other countries. That’s important.
I think within my own advocacy, I’m conscious that the sort of patient advocates you tend to meet are all a bit similar, and we do need to work harder to bring in a wider range of voices there. We need people from different cultures and different socio-economic backgrounds to come together and be able to feel that they are of an equal contribution in conversations about this. And I think part of that is making sure that their time is recognised and the value of their expertise is recognised. For example, it’s definitely good practice these days to offer an activity payment. For example, if someone’s got a regular advocacy role as an advisor with a particular organisation, it’s important to make sure that there’s an offer to pay for their time. Whether they take it up is entirely up to them, and in some cases, people who are already on other benefits might choose not to take that funding offer up because it would jeopardise the other things that they might already be benefiting from. But as a general principle, I think it’s really important to recognise that, because somebody who’s relying on earnings from another role is not going to step away from that to come and talk at your meeting unless they can afford to do it. And so in order to try and level the playing field a bit, I think offering to fund advocates time is really important, and some organisations do it very well, and some organisations have yet got some way to go.
Manuel: If I may very quickly follow up from that, because there’ll be some communities that may be even suspicious about this kind of potential treatment. You know, there’s been exploitation and abuses in the past, and there’s also the perception of “white, rich, Western-driven” science being imposed onto different cultures. This is something that I’m not expecting you to give us an answer to, because it’s a very complex, ethical, social answer. I mean, as a researcher, this is something that I am extremely interested in understanding, and perhaps you may have some perspectives as a patient advocate that we could incorporate.
Jillian: One of the first things that springs to mind is the work that the Australian National Centre for Indigenous Genomics is doing. They’ve done some incredible work there. The collection of genomes that they have was collected through blood samples from people who are First Nation Australian, and in some cases, the consent for that wasn’t entirely clear. It was now several decades ago that this was done, and there was a more recent recognition that people from those communities should be involved in deciding what happened to that data. And so now they have an oversight Steering Group, which is more than 50% First Nations community reps. And I think they’ve been able to bring their own cultural understanding and their own cultural roots into the discussions around that delivery of genomic medicine in Australia, which is amazing. And they’ve done some work recently where they produced some explainer videos for their own community. Again, new analogies for what genomics is in terms that are going to resonate with the communities that they live in. That’s really interesting stuff and it’s really helpful to share further examples around the world of different ways of conceiving the concepts of this, because the analogies that are going to mean something good to one group of people won’t necessarily work with others. So, it’s in everybody’s interest, if we can keep generating more and touching more bases in that way.
Manuel: Yes, I know about the Australian Indigenous initiatives, and I found them incredibly respectful. I also know about the Silent Genomes initiative that is happening in Canada. But one of the things that strikes me is that all these initiatives have something in common: they are all in the Global North. And I think it even happens at the level of the UK, you know, it’s rich communities versus poor communities. It’s a lot harder to reach poor communities. We say with the UK Biobank, it’s just that the people who are more likely to respond are healthier, higher socio-economic status. And it’s not an easy solution here. I wonder if you’ve had any contacts with patient advocates in the UK, from say Bangladeshi or Pakistani backgrounds. You know, how can we make them feel more included?
Jillian: Yeah, it’s a really good question. We can talk about how important it is to include a diversity of voices, but if we haven’t got the systems and the mindset ready to receive those then it’s not going to work. And in some cases, I think you can put out an offer to invite somebody to come and be part of a conversation, but if it doesn’t fit with their way of living, then they’re not going to be able to even come and think about it. So, I think meeting people where they are is the principle which is most useful there, going out to communities, finding the community leaders, talking to them about what matters in their communities and how to reflect that in what you do as an organisation, seems to be the more fruitful way forward. And I know that the Generation Study, which is currently sequencing so many newborns through the Genomics England programme, they’ve put an enormous amount of effort and care and respect into the materials that they’ve been developing to try and specifically broaden the appeal of that study to a much wider range of different groups. And whilst there, while I was still at the Participant Panel, we were aware that there was a lot of community advocacy work going on as a parallel track, rather than being part of the Panel’s activities. They were identifying and developing community advocates from some of the minority ethnic group communities to work directly with them, to make sure that the messaging that they were trying to share was going to be appropriate and useful to the people who they were trying to reach. And I think that’s been successful, although I’m sure you should get somebody from there onto your podcast at some point to talk to them!
I think what you were saying about the Global North is really valid. And some of the things I have heard about this year, partly as part of trying to pull together some good case studies for the course I’m leading, there’s some great things going on in North Africa as well. The PerMediNA – Personalised Medicine in North Africa Initiative – is bringing together people from the North African countries and sharing a lot of information with the patient population there in lots of different languages and having to reach out in different terms. And there’s also been quite a lot of work happening in Sub Saharan Africa, with the Sickle Cell Warriors, who have been quite active in informing policy in different countries, as well as helping to produce patient facing materials and wider public facing material to try and break down some of the stigma that has been associated with sickle cell around the world, really, over the past decades. I suppose it’s harder for us to hear in Britain about some of these initiatives, but there are people working on those sorts of things out there too. And I think that having organisations that have a global reach to be able to help support those is really important.
Lyndsey: You’ve mentioned opportunities for collaboration; you mentioned earlier the case study around people coming together to name a condition in a way that resonated with people. What are some other opportunities for collaboration? Do you think they differ between academia and pharma? And I’d be interested to see, Paul, if you have any perspectives on that as well, from a part a pharma point of view?
Paul: I think, as a general rule, the pharma industry is becoming more patient centric over the years. For a lot of reasons, in that it’s the right thing to do, that it’s the way to make medicines more effective, that patients are a resource, not just in the sense of something to be used in there, but they’re also a source of knowledge. But you know, it is still a very long road there, I think. And there are many old habits that could keep us back in the old way, the production line model of medicine – knowledge goes in one end, a drug comes off the other end and it’s shipped off like fries at a fast-food restaurant and so forth. But I do believe that there are changes taking place, but it will, as with everything with these very large corporations and these large industries, take time.
Jillian: Do you see examples in the pharmaceutical industry where you think it’s worked particularly well to be engaging with patient communities?
Paul: So, I think just the existence of patient organisations, as you’ve said, is in a very important thing. And your comment earlier about names, just being able to put a name to a condition or a disease is a very important thing. Because that gives you something to gather around in the wider sphere. I think a good place for patient organisations to interact with is not necessarily individual, large pharma companies, but it’s with things like research consortiums or precompetitive consortiums or things like that, because then you’re not just talking to one person or one entity or anything like that, you’re talking to a whole group of people who will often have this diversity of knowledge around the subject. And there is also, in that case, there’s a bit more of an element of ‘Company A is doing that, so we have to do that as well.’ Let’s not diminish the effect of just a cheap bit of psychology there. You know, rather than trying to turn around the industry, go company by company, and if you can talk to a whole bunch of them at once, I think that’s much more powerful and it’s taking place in public as well.
Jillian: I suppose, in the same way that lots of people don’t know about genetics and genomics, lots of people don’t know about how drugs are developed yet either. I know that there’s a lot of patient training courses now; I did one this year, and I’ve signed up for another one next year. But, you know, understanding the drug development process in more depth, you can begin to understand where you as a patient advocate or as a community representative can start to feed into conversations at a stage that really matters. And I’m looking forward to learning more about it. Working with patient groups and community representatives when you’re still talking about what the outcome measures should be when you’re developing a new drug is absolutely invaluable, I would have thought, and I think I’ve only been tangentially involved in conversations like that so far, but I feel like that seems to be a real fertile ground for collaboration.
Paul: I think you bring up two really good things in there. Number one, the opaque, strange way that our drugs are developed, that very few people actually understand. And you know, in a way, it’s even more difficult to understand than genomics, because it’s a murky industrial process. And so you get these great misunderstandings about how drugs are made, such as we saw during the pandemic. And there’s that other very good point you made: what are the outcome metrics that we use when we’re testing drugs, when we’re putting drugs through trials? All those things like that, we need something to measure in order to say how successful has the drug been, and so forth. And I guess, in a traditional sense, we’ve tended to head towards these very easy to measure things. You know, for a cancer patient, how much longer will they survive? For an asthma patient, how many times will they cough, or something of the sort. But as every patient on a complex drug knows, that’s a great simplification. What are the side effects? What’s the burden of that drug? If you’re a patient a who has a very difficult to treat cancer, one of the things that you want to emphasise is its impact on your life, on your general wellbeing. You don’t want to be sick from chemo all the time, or you want as long a period as possible between treatments. Looking at those things allows us to step away from these pure qualitative measures, the cold numbers, and look at things like, what is it that people actually want? What is it that’s making their lives better? And those are somewhat more difficult to measure, but they’re not impossible to measure, and patient organisations can absolutely help pharma companies get a better grip on those.
Jillian: One thing from my experience has been that the measurement scales that are used seem to be in ladders which have too much space between the rungs. So even if my child, or a child I know, is on a drug trial, and they’re making fabulous progress, if they’re not going to make enough progress to hit the next rung on the measurement ladder, that’s still going to fail as part of the quantitative information that you’re collecting in the study. What I would love to see is more fine grained measurement scales being agreed across the industry that we can then apply in different drug trials so that, especially where it’s around children, and especially children who are non-verbal, you can assess how life changes for them if they have a particular form of treatment. What are the very fine grain inch stones that we might be able to measure that against, to start being able to develop proof that even if they’re not going to be getting up and walking somewhere, that life has improved significantly as a consequence of this drug trial? That’s what I would love to see.
Paul: Anytime you’re dealing with children, let alone children who are non-verbal, it’s very difficult to measure these things. So now, how can we make that better? How can we make that more apt to the circumstances that you’re in? You know, when in the bad old days, and to a certain extent, in our current days, what you do is you plunk the child down in front of physician who, as you would know, would measure a certain something on a scale of one to five. What’s the child’s muscle tone, or what’s the child’s degree to control that movement and so forth. And that is necessarily crude in there. How do we do better by that? And that’s something that will benefit not just patients, but also benefit the people who are making the drugs as well.
Manuel: I had another question. Now, looking a little bit more into the future, Jillian, you’ve done a huge amount of work in terms of patient advocacy, from being an outsider, now, in some respects, you are a role model for many families. So, from your own perspective, what are the next things that you’d like to make happen in the next few years. What are the sort of projects or changes that you are working towards in the next few years?
Jillian: What I would love to see in the next few years would be the recognition that we need to keep bringing real people into real conversations. I really worry about the rise of AI and all of the sort of things we see now about well, perhaps we can get an AI to tell us what the patient group are thinking. Or perhaps we can use a chat bot as a genetic counsellor. And you know, I’m sure somebody out there is well meaning and trying to spend a lot of their professional time developing that sort of thing, but the human to human connections are more important now than they’ve ever been, and yet, I feel we’re facing the challenge there that AI seems to be now applying to all scenarios. And I’m not saying it’s not useful in some of them, certainly in bioinformatics and diagnostics and all these sorts of capacities, AI is saving a lot of people a lot of time and is adding value, but in terms of that connection between researchers and clinicians and scientists and the people who are living with the conditions that they are trying to address, we’ve got to make sure that there’s still real connections there, and I would love to see more opportunities for that to happen, in a way. We have all the hype and the buzzwords. And I know that you were saying, Paul, about patient centricity, particularly being a term that you hear everywhere now, I do think there can be a danger that it does become such a buzzword that people become blind to it again, like sustainability was 15 years ago. ‘Well, of course we’re going to do that’. But in terms of what it really means for people who are really living with these disorders, and the opportunities that they may or may not have to actually engage with people who have the skills to help them, I think we could do more there. I don’t have a grand plan, but my feeling is that that is an area where there’s a lot of work that could still be done to benefit people.
Manuel: I’ve already said this in public. I lose sleep thinking about AI. I’m not sure about you guys, but there’s no day I’m not doing any kind of thinking or doing with AI these days, every single day, consciously. My main worry is actually the amplification of existing disparities and inequities and biases, and that concentration of so much power into very, very, very few hands who will make decisions that will shape the future of our human race. You’ve mentioned that human connection, the risk of being substituted by some kind of agent, some kind of AI. But how does that look in practice? What would be good illustrations of the objectives and the sort of things that we want to achieve for the future of rare genomic disorders? This, and genomic medicine in general, what does it look like in your eyes? More contact?
Jillian: Yes, more contact and time and space to understand more about the context of somebody, whether that’s the researcher, whether that’s the patient or the family, to have the opportunity to see around the back of somebody. If we’re going to go using the AI example, again, you can probably synthesise my face quite easily and turn me into something else that could say anything, but you can’t see the back of my head, and you can’t see what’s in my heart. And I think being able to have time to still think about those things and share those things at a human level would be important. And you know, if we can get the machines to do all the mechanised routine, boring stuff, and leave ourselves time to have these qualitative conversations, wouldn’t that be wonderful? I suspect that may be an overly optimistic view.
I think there’s a lot of information out there on the internet now, which newly diagnosed families are still looking to find. And I’m sure everybody who’s had a diagnosis in the last couple of years has put it straight into ChatGPT and said, what can you tell me about this and what it means for my family? And I don’t know who’s policing the veracity of that, and I don’t know who is gate keeping the feelings around that. And maybe there isn’t anybody. Maybe this is where the danger lies, that somebody, who 10-15 years ago could have typed a string of letters into Google and it would just pop up with two academic papers and a coffee meet somewhere in America, now gets totally inundated with too much information, and too much of that information is either too generic or sort of thoughtlessly damaging. In the sense that information for patients, when you’re first in a world where you have a new diagnosis, that in itself is very frightening, and so you’re very sensitive to any more bad news or a difficult future picture popping up on your horizon. And I think one of the great things that patient support groups can do in that space is to try and gate keep to some extent, and help take people through the journey of learning more about this without terrifying anybody at the beginning, because I think there’s still too much written by people who don’t understand the patient experience, which may be excellent science and may set out very exact information about life expectancy, for example, or the severity of symptoms, all that kind of thing. But they weren’t necessarily thinking about who else might read that, and if it gets into the hands of a family at their new diagnosis, that could just be crushing.
Paul: You know, as you said, it’s all out there. And as what does that mean? And for every story that there is out there about someone with a mysterious illness punching the symptoms into ChatGPT and getting a diagnosis back, and that being a victory, there is an accompanying case of someone doing the same and being completely misled. You know, no sword without an edge.
Manuel: You just were reminding me of when my son was first diagnosed with Down syndrome. You know, they’re going to tell you all the things that are going to go wrong. He’s going to have heart disease, die young, he’s going to have all of those 300 things. In the end, maybe two or three happened, if at all. And that’s the thing that you were saying, about basically being taken by hand and walking the journey, learning about the implications from the human perspective. Because a lot of the time – and I’m not blaming the physicians, the doctors – they have to cover their backs, and they’re gonna give you all of these things so they don’t get sued or whatever. They would not even give us an equivocal diagnosis, even though you could see the symptoms. So, I mean, this is something that, from my perspective, really illustrates the need for patient advocacy groups where there’s that sort of, I guess, legal pressure of having to cover the boxes and so on.
The other thing that hasn’t been mentioned in this conversation about the use of AI is the risk of hallucinations. You know how, how difficult it is to see things that apparently look bona fide, and then you have to be extremely careful to interpret the results that you get from any query.
Jillian: I would really be interested to hear a little bit from your perspective about what you think it would be helpful to hear from patient advocates and patient communities in the work that you’re doing. Is there something that you wish you were able to hear more about that you don’t, or is it hard to find people in this community to talk to? What do you think we as an advocacy community and as a group of patient groups could do?
Paul: There’s been a couple of cases where, if you investigate a patient population, if you talk to a patient organisation, you find out that a particular drug is not working as expected, or it doesn’t work in everyone, or even occasionally there’s been a few cases where patients have found another drug that, via off label use, has helped them. These things are obviously great. But how do we make that work better? How do we not rely upon just serendipity to trip upon these things, that could only be a great boost to the drug development process?
Jillian: I think that part of the answer I would give you to that, Paul, would be building up sustainable relationships with the patient communities, so that you have a group of people you can go back to after a period of time has passed, and check in with them and see how things have gone, if they’re taking the drug, for example, or if they’re in a community which had an opportunity to take that drug, and for whatever reason, stopped taking that and went for something else.
Manuel: I’m going to be a little bit ruthless here. I don’t think that we researchers are sufficiently aware of [patient advocacy groups]. I’ve seen some events, in the Genomics England summit for instance. Generally speaking, I think patient engagement is absent in most events. I think there should be much greater visibility. Even in education programmes, universities or part of the research training activities by organisations, funded organisations, they are almost invisible, I would say. From my perspective, that needs to change. There’s also a little bit of, as you will probably recognise, a little bit of box ticking. So, how can we make sure that the actual engagement with patient advocates is not just a box ticking exercise, you know? Because at the end of the day, that is the core of what we are trying to do as research scientists, and we are here because we want to improve the life of patients. So, I think, from my perspective, much more work needs to be done in terms of communicating and making them more involved in the decisions as scientists. A lot of the time we, as you said, we name things, we make classifications, we label things, having no idea about the circumstances, the lives, the needs of the people we are trying to serve. There’s a lot of education and engagement that needs to be put forward that obviously requires lots of money and time. But I think, if we are able to keep talking about it, if we are able to give you a voice, you are able to tell the world of the wonderful things and the wonderful changes that people are like you are making, perhaps we can change things for the better.
Jillian: That’s a wonderful speech. I really I’m getting lots of great ideas off the back of it. You know, if I win the lottery, I can set up some kind of consultancy business where I could bring in everybody I know from the patient advocacy world, and we could be a super team so that anybody anywhere who wanted to hear about a particular patient experience, we could suddenly find somebody who could parachute in and share that with them. But I think I’m going to have to keep dreaming about that one! I think in practical terms, the thing which leads to success in that space most effectively is buy in from the senior leadership, that having sustained conversations with a group of people who have lived experience of the conditions that you’re interested in over a period of time are worth investing in and are worth supporting. Although they’re not necessarily going to be able to demonstrate a line on a budget somewhere that says ‘this is the benefit we have managed to accrue as a consequence of engaging with these people over this period of time’ – the value that you’re adding to the organisation and to the mindset is unquantifiable and potentially very great. And so having that senior buy in and building sustainable relationships there, and understanding that the people who want to talk to you aren’t necessarily always the people that you should be hearing from, and putting in the extra effort to find the people who you should be hearing from, it’s worth doing.
There was a paper that we wrote in the end of 2022 which appeared in the European Journal of Human Genetics, and that was talking about the Participant Panel’s experience up to that point, about what the success factors had been in the Panel’s establishment, and in how we’ve been instrumental in making sure that the patient perspective and the research participant perspective are percolated through to lots of different activities within Genomics England. And having senior level buy in, and having somebody within the organisation who was effectively the conduit for those sorts of conversations, was really helpful. Having somebody in the organisation who knows that there is a community of people out there who are keen to share their experience and can also be cited at a senior enough level within the organisation to understand what various parts of it are doing, and to connect those up, is really important. I think some organisations make the mistake of assuming that having an engagement manager who’s a very junior rank of an administrative officer level, trying to be the person who is the conduit for all that vast wealth of lived experience into the organisation, isn’t sufficient. I think you really need senior leadership to understand what these people with the lived experience are bringing to the conversations, and to be able to speak to them directly. That’s really very important.
Manuel: Is the paper ‘Research participants, critical friends, agents for change’?
Jillian: That’s exactly the one.
Manuel: Everyone listening. Please read this paper. I’m going to. I’ve got a final question. Jillian, you were awarded the MBE for your work in patient advocacy. This is an extraordinary recognition. How has that changed your life, both personally and in the way people engage with you as an advocate?
Jillian: Yeah, I’m still processing, really, but it was a wonderful thing that the work that I put in for the preceding seven or eight years with the Participant Panel and beyond had been recognised by the people I’d been working with and in the wider genomics world. Yeah, that was really lovely. You never really know what impact you’re having, beyond the conversations that you were part of directly, until you hear something like that coming back to you and yes, it was wonderful to hear that the things I’d said in the right ears at the right time had landed somewhere and had, in some cases, generated new ideas, which had gone on and turned into something useful. I suppose it means that people, at the moment, at least, see me as somebody who they can talk to you about these things. And perhaps. I don’t know, do I count as an expert? I never know if I feel like one! But yeah, I think I was really fortunate to be able to land in the Participant Panel when it started, and I was very fortunate to have the support of my husband and my own social networks that enabled me to have the time to come and do as much as I did, and the sharp elbows to break into the conversations and to try and put myself in a meeting and then really make the most of being there. And, you know, whether it’s the initial meeting that we had a couple of years ago now, with the people who were organising a particular conference, and me saying,’ Well, why don’t you have actual participants introducing some of the stages?’ And you know, no one had ever suggested that to them, but they were like, yeah, okay, let’s do that. And I think that changed the tone of an event, if you can put people who are living with these things right on the front of the stage. A lot of it’s just been little incremental things that just come to something good. I suppose there’s pressure now that I’ve got this wonderful bag, that people are going to expect me to continue to be the expert in this field. And I think that is not necessarily going to be true. It depends, you’re only as good as the thing you did yesterday, so we’ll see. But I’m still really keen to be involved and genomics itself is still a really exciting field to be in. There’s so much still developing, and there’s so much more for us to learn, but there’s also so much more to try and make sure that these patient voices and the participant voices are feeding into the right conversations at the right time. So, I certainly don’t see the kind of work that I’ve been doing becoming less important as time goes by. I’m just confident that there are other people out there taking it forward in these other official channels. At the moment, we are well placed to carry that legacy on.
Manuel: Well, the fact that you mentioned splicing variants and that you have a first author in the European Journal of Human Genetics, I’m not sure if that is not an expert to me, I mean, that sounds pretty expert!
Jillian: In a limited and specific way, I’ll take it! I know that it’s become a bit of a cliche to say that genomics is a team sport, but I am the first person who put that in print in the paper that you’ve just referred to. I was really pleased to be able to do that, because it’s something which does percolate through now, this feeling that all the different specialists that we’ve got feeding into the mission of genomics are all there because they all need to be there, and that list of people who are included has to include the people whose data are powering these discoveries. That, to me, is a wonderful thing.
Lyndsey: Jillian, thank you so much for your time today. It’s been a really exciting conversation. And you mentioned earlier that you’re an optimist, and I think that really just shines through in what you say. And I think that provides so much hope for people, especially the people who are going to be listening to this. So, I’d just like to remind everybody Jillian’s course will be going live on, I believe you said the 22nd of September? I would encourage everybody to check it out and check out the paper mentioned earlier. Thank you again, Jillian.
Find us on Spotify or Apple Podcasts now.


